Navigation Links
New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
Date:4/4/2011

RIDGEFIELD, Conn., April 4, 2011 /PRNewswire/ -- Two new retrospective subanalyses of the RE-LY® trial, involving Pradaxa® (dabigatran etexilate mesylate) capsules, suggested that the reduction in stroke risk achieved with PRADAXA 150mg over warfarin (1) occurred irrespective of CHA2DS2-VASc risk score (2) and the type of non-valvular atrial fibrillation (NVAF) (permanent, persistent and paroxysmal)(3).  The results were presented at the American College of Cardiology's 60th Annual Scientific Session. (2,3)  

The first subanalysis assessed the impact of the novel CHA2DS2-VASc risk score,(2) which determines stroke risk based on age, sex and the presence of comorbidities,(4) on outcomes in the RE-LY trial.  Patients were grouped into quartiles based on CHA2DS2-VASc score (0-2, 3, 4, 5-9) (2) and results showed that PRADAXA 150mg was associated with reductions in stroke risk compared to warfarin for all four quartiles (0-2, RR = 0.63; 3, RR = 0.61; 4, RR = 0.53; 5-9, RR = 0.77; interaction p-value = 0.60).(2) Results of the analysis showed there was a significant interaction between CHA2DS2-VASc score and rates of major bleeding, with lower rates for PRADAXA 150mg compared to warfarin for patients in the first three quartiles, but an increased rate of major bleeding for the quartile at greatest risk (0-2, RR = 0.75; 3, RR = 0.74; 4, RR = 0.83; 5-9, RR = 1.33; interaction p-value = 0.003).(2)

"This analysis suggests that PRADAXA 150mg taken twice daily may reduce the risk of stroke compared to warfarin across the levels of NVAF-associated stroke risk, as determined by the CHA2DS2-VASc score," said Paul Reilly, Ph.D., clinical program director, Boehringer Ingelheim Pharmaceuticals, Inc.  "These findings are important because the risk of stroke in patients with NVAF increases significantly with the presence of comorbidities, such as diabetes or hypertension."

PRADAXA was also evaluated in a second RE-LY suban
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Sub-Analysis of RE-LY Trial Examines Pradaxa in Patients with Atrial Fibrillation Undergoing Cardioversion
2. New Analyses of Data From RE-LY Trial, Involving Oral Anticoagulant Pradaxa, to be Presented at American Heart Associations Scientific Sessions
3. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
4. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
5. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
6. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
7. Boston Scientific ION™ Platinum Chromium Stent System Demonstrates Strong Performance in Analysis of PERSEUS and TAXUS ATLAS Clinical Trial Data
8. Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
9. REMEDIAL II Results on PLC Systems RenalGuard® to be Presented at ACC 2011s Late Breaking Clinical Trial Session
10. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
11. Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- ChemImage will ... the Australian and New Zealand Forensic Science Society,s ... Sciences in Adelaide, Australia . ... concerning the advancements that hyperspectral imaging can bring ... Jeffrey Beckstead , Director of Product Development at ...
(Date:8/29/2014)... British Columbia and MENLO PARK, ... DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the ... fiscal year-end financial statements.  The Company recently changed its ... facilitate an application to list its common stock on ... DelMar,s financial statements as filed with the ...
(Date:8/28/2014)... Aug. 28, 2014 Reportlinker.com announces that ... its catalogue: North America Aesthetic Lasers ... http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html North ... to 2020 Summary GlobalData,s new report, ... Outlook to 2020", provides key market data on ...
Breaking Medicine Technology:ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today a ... Phase 3 study required for New Drug Application (NDA) ... 140 patients has greater than 90% power to detect ... to enrol additional patients. QRxPharma anticipates completing analysis of ...
... or "Company") (Nasdaq: UNIS, ASX: UNS), today announced that ... clearance from the U.S. Food and Drug Administration (FDA). ... variant of the Unitract™ 1mL Insulin Syringe for which ... syringes which are primarily used by people with diabetes, ...
Cached Medicine Technology:QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 2QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR 3Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 2Unilife Corporation Secures FDA 510k Clearance for the Unitract™ 1mL Tuberculin Syringe 3
(Date:8/30/2014)... (PRWEB) August 30, 2014 Daily Gossip reveals ... the Make Him Desire You program, who shows a unique ... The author of this method says that the program goes ... The Make Him Desire You review indicates that the program ... insider advice and his great techniques to make a man ...
(Date:8/30/2014)... Albany, New York (PRWEB) August 30, 2014 ... a combination of Nutrition and Pharameuticals. Nutraceuticals is ... by extracting healthy ingredients from natural food sources. ... specific health benefits to the human body. Nutraceutical ... multivitamins, diet supplements, fortified foods and more. Although ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... York, New York (PRWEB) August 30, 2014 ... other incretin mimetic claims continue to move forward in ... statement issued by AstraZeneca PLC on July 31, 2014, ... been named in 409 product liability claims that allege ... Court documents indicate that many of these claims are ...
(Date:8/30/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... say , , MONDAY, Dec. 1 (HealthDay News) -- ... non-invasive treatment for the painful foot condition known ... "dry-needling" and steroid injections guided by ultrasound, the ... success rate in tackling a condition that afflicts ...
... NASHVILLE, Tenn., Dec. 1 Medication therapy management,(MTM) provider ... , New members ... Burcham; and Kevin Hutchinson. The three join an ... hone its MTM services, which work,to guard against medication ...
... Dec. 1 Seniors who take a close look ... plans may still realize,savings next year. Medicare HMO ... $0 monthly premiums and $0 deductibles with partial coverage,throughout ... of their,drug bills until reaching $4,350 in out-of-pocket costs). ...
... Dec. 1 The next time you visit a dentist,in ... blood pressure,in addition to your brushing habits. , ... Medical Center/McLaren Health,Care and the Michigan Primary Care Association are ... together more closely on,detecting high blood pressure in patients. , ...
... stenosis, according to a large study performed at Leiden ... The study consisted of 1,331 patients who had suspected ... coronary artery segments were analyzed during the study. "We ... artery stenosis in our patients; specificity was 91%," said ...
... UCLA study shows for the first time how microscopic crystals ... at the ends of cilia tiny cellular hairs in ... play an important role in detecting sound, maintaining balance and ... to blame for the most common form of vertigo. Known ...
Cached Medicine News:Health News:New Twist on Treatment of Foot Pain 2Health News:New Twist on Treatment of Foot Pain 3Health News:PharmMD Expands Advisory Board 2Health News:HealthMetrix Research Finds Medicare Advantage Plans Offer Seniors Opportunity to Lower Their 2009 Out-of-Pocket Drug Costs 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 2Health News:Dental and Medical Communities Piloting Partnership in Mid-Michigan To Detect and Defeat Disease 3Health News:Can you hear me now? How the inner ear's sensors are made 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: